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Case RepoRt
Polyagglutination is a rare and underdiagnosed condition, 
characterized by agglutination of red blood cells (RBCs) with 
almost all ABO-compatible adult sera. Polyagglutination can 
occur when a cryptantigen is exposed on RBCs via microbial 
enzyme activity. Because nearly all adults naturally produce 
antibodies against cryptantigens, transfusion of plasma can cause 
unexpected hemolysis and hematologic complications, such as 
thrombocytopenia and disseminated intravascular coagulation, 
in patients whose cryptantigens are exposed. We report a case 
of Glycine soja polyagglutination occurring in a 60-year-old 
African-American man with disseminated methicillin-resistant 
Staphylococcus aureus (MRSA) infection. Prior to transfusion, 
the patient developed severe anemia of unknown etiology. 
Following transfusion of 3 units of fresh frozen plasma (FFP), his 
RBC count could not be determined for 24 days because of RBC 
agglutination in his blood sample. In addition, the FFP transfusion 
correlated with the rapid development of severe, transfusion-
refractory thrombocytopenia and anemia. The perplexed clinic-
al team consulted the blood bank. A direct antiglobulin test 
demonstrated 1+ mixed-field reactivity with both monoclonal 
anti-IgG and anti-C3d. Lectin panel testing showed reactivity 
with only Glycine soja, confirming the condition. Subsequently, 
plasma components were avoided, and RBC and platelet (PLT) 
components were washed prior to transfusion. After a 44-day 
hospitalization involving the transfusion of 22 units of RBCs and 
13 units of PLTs, the patient was discharged to a long-term care 
facility. The patient’s confounding hematologic complications 
can best be explained by polyagglutination, which developed 
secondary to the severe MRSA infection. The FFP transfusion 
likely passively transferred antibodies that bound to the patient’s 
RBC cryptantigens, leading to RBC agglutination and anemia. 
The development of severe thrombocytopenia may be related to 
cryptantigen exposure on the patient’s PLTs. Although difficult to 
identify, polyagglutination needs to be recognized to appropriately 
manage hemotherapy. The purpose of this case study is to report 
hematologic complications following FFP transfusion in a patient 
with Glycine soja polyagglutination, a rarely described condition. 
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Polyagglutination describes the agglutination of red blood 
cells (RBCs) that occurs with nearly all compatible adult 
sera.1,2 It arises through an alteration of glycoprotein moieties 
on the RBC membrane. This condition is usually secondary 
to infection1,2 rather than to a congenital or somatic mutation. 
T activation is the most common form of microbial-induced 
polyagglutination and serves as a prototypical example 
(Fig. 1).3 Antibodies against cryptantigens are naturally 
occurring and are usually IgM.3 The patient’s own antibodies 
may mediate hemolysis.4 However, it is more common for 
hemolysis to occur after the transfusion of blood components 
that contain plasma.5–7 Thrombocytopenia may develop 
because of the presence of the cryptantigen on platelets 
(PLTs).8,9 In addition, coagulopathies, such as disseminated 
intravascular coagulation (DIC), often occur.5,10
In the past, polyagglutination was readily detected by blood 
centers when ABO typing resulted in ABO discrepancies.8,11 
This finding occurred because human-source sera containing 
antibodies against cryptantigens were used for blood typing. 
The transition to monoclonal antibodies for blood typing 
Fig. 1 Microbial enzymes such as sialidases (circle sector shape) 
can enzymatically remove N-acetylneuraminic acid (triangles) from 
RBC antigens. This action exposes normally hidden cryptantigens, 
such as T (shown on the right), which can subsequently bind anti-T. 
This particular type of polyagglutination is known as T activation. 
This form is often described in pediatric patients with necrotizing 
enterocolitis or atypical hemolytic uremic syndrome caused by 
Streptococcus pneumoniae. T is also present on platelets and 
glomerular endothelial cells. The circle designates d-galactose. The 
square designates N-acetyl-d-galactosamine. R = Remainder of 
molecule; RBC = red blood cell.
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eliminated these ABO discrepancies. In addition, most 
blood centers do not routinely screen for polyagglutination.12 
Therefore, polyagglutination is becoming under-recognized. 
To identify polyagglutination, the condition must be suspected 
by either clinicians or blood bank personnel, and additional 
testing must then be performed. Additional features seen in 
polyagglutination include a C3-positive direct antiglobulin test 
(DAT) and/or a reverse ABO typing discrepancy.1,8 
Lectin panel testing should be used to properly identify 
and classify polyagglutination.1,2 Lectins are proteins that bind 
to carbohydrate antigens.13 Lectin panel testing is not available 
in most blood banks, although this testing is performed by 
reference laboratories. Alternatively, polyagglutination can 
be more easily detected by demonstrating RBC agglutination 
with nearly all compatible adult sera. In rare cases, RBCs from 
patients with polyagglutination are not truly polyagglutinable, 
and polyagglutination can only be diagnosed using lectins.2
Suspected polyagglutination may prompt the use of 
specialized transfusion protocols to minimize the passive 
transfer of antibodies targeting cryptantigens. Protocols 
involve avoiding plasma components and washing units of 
RBCs and PLTs.12,14 If plasma components must be given, the 
least incompatible units, as determined by minor crossmatch, 
should be selected. In addition, blood components should 
be transfused slowly with careful monitoring of the patient. 
For critically ill patients, plasma exchange using albumin 
as the replacement fluid9 and RBC exchange using washed 
RBCs12 have been reported as beneficial. Nevertheless, 
these transfusion practices are not universally accepted 
because of skepticism about a causal relationship between 
polyagglutination and hemolysis.3,12 In addition, some 
physicians note risks associated with avoiding therapeutic 
blood components and with the time delay caused by washing. 
In addition, washing can lead to bacterial contamination, the 
loss of 20 percent of RBCs, the loss of 25 percent of PLTs, 
and impaired hemostatic function of PLTs.14 Also, reports of 
uneventful transfusion of plasma components15 have led some 
physicians to discount the potential risks of transfusion.
Case Report
A 60-year-old African-American man with a past medical 
history of epileptic seizures developed methicillin-resistant 
Staphylococcus aureus (MRSA) endocarditis involving the 
free wall of the right atrium, with secondary seeding of the 
left knee. The patient was treated with intravenous antibiotics 
(vancomycin and piperacillin-tazobactam) and underwent 
two incision and drainage (I&D) procedures of the septic 
knee. Subsequently, his hemoglobin declined from 11.4 to 
7.1 g/dL (reference range: 14.0–18.0 g/dL) for unknown 
reasons (Fig. 2). The patient’s blood typed as group A, D+, 
and multiple RBC units were transfused. Before the third I&D 
procedure, the patient received 3 units of fresh frozen plasma 
(FFP) for reversal of warfarin, which was being given for a 
thrombus that formed over the cardiac vegetation.
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Fig. 2 Hematology values throughout the hospital course. (A) 
The WBC count peaked early in the hospital stay. The patient 
remained febrile throughout the hospitalization, however, developing 
disseminated infections involving the lungs, soft tissues, and 
bones. (B) The RBC count, including the mean corpuscular volume 
(MCV), mean corpuscular hemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC), and red blood cell distribution 
width (RDW), could not be reported for 24 days after the transfusion 
of FFP because of agglutination in the patient’s blood sample, 
refractory to 37°C warming. (C) Mild thrombocytosis developed into 
severe thrombocytopenia over 9 days after the transfusion of FFP. (D) 
The persistently declining hemoglobin was managed with numerous 
RBC transfusions throughout the hospitalization, several of which 
were with washed RBC units. Anti-M and anti-E were subsequently 
identified; anti-K could not be excluded. WBC = white blood cell; 
Tmax = maximum temperature; RBC = red blood cell; FFP = fresh 
frozen plasma; PLT = platelet; IVIG = intravenous immunoglobulin; 
DEX = dexamethasone; # = number of units transfused; Hgb = 
hemoglobin; Ab ID = antibody identification. *Anti-K could not be 
excluded.
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Following the FFP transfusion, the RBC indices could not 
be reported because of RBC agglutination in the patient’s blood 
sample (Fig. 3), refractory to 37°C warming. Peripheral blood 
smears revealed large irregular clusters of RBCs, consistent 
with agglutination rather than rouleaux. No spherocytes or 
schistocytes were identified. After the FFP transfusion, his 
hemoglobin dropped from 8.1 to 5.6 g/dL. Upon retyping, 
the RBCs were 4+ reactive with anti-A reagent (Gamma-
clone, ImmucorGamma, Norcross, GA) and weakly reactive 
with anti-B reagent (Gamma-clone, ImmucorGamma), 
representing a forward ABO type discrepancy. In addition, 
the patient’s sera was 3+ reactive with B cells (Referencells, 
ImmucorGamma) and weakly reactive with A1 cells 
(Referencells, ImmucorGamma). The reactivity with reagent 
A1 cells was not previously seen. The antibody screen was 
negative when using a 45-minute pre-warm method without 
polyethylene glycol enhancement.
To address the unexplained anemia, 8 units of RBCs were 
transfused over 5 days. Because the clinical team suspected 
bleeding rather than hemolysis, relevant laboratory values 
were only obtained at the beginning of this episode. These 
labs demonstrated a total bilirubin of 1.3 mg/dL (reference 
range: 0.3–1.2 mg/dL); lactic acid dehydrogenase (LDH) of 
377 U/L (reference range: 120–246 U/L); and a haptoglobin 
of 177 mg/dL (reference range: 40–240 mg/dL), which was 
greater than 340 mg/dL prior to the FFP transfusion. A fecal 
occult blood test and urinalysis did not identify a source of 
bleeding. In addition, a computed tomography scan revealed 
only a small hematoma of the left thigh. The FFP transfusion 
also correlated with a rapidly declining PLT count, which 
was 472,000/mm3 (reference range: 150,000–400,000/
mm3) prior to transfusion, and 8000/mm3 9 days later. DIC 
was not favored as contributory to the thrombocytopenia 
because of the absence of schistocytes on peripheral blood 
films. Heparin was discontinued, even though the anti-platelet 
factor 4/heparin antibody test was negative. Perplexed by the 
hematologic complications, the clinical team consulted the 
blood bank.
The transfusion medicine service considered 
polyagglutination in the differential diagnosis. A DAT was 
performed and demonstrated 1+ mixed-field reactivity with 
polyspecific anti-human globulin (AHG), monoclonal anti-
IgG, and anti-C3d. Next, a sample with a request for lectin 
panel testing was sent to a reference laboratory. Chloroquine-
treated patient RBCs were weakly reactive with four sources 
of group AB plasma/sera at albumin (ALB)-37°C phase, 
including the diluent control, but were nonreactive at 
immediate spin (IS), room temperature incubation (RT), and 
ALB-IgG AHG phases.  Patient plasma reacted with group A1, 
A2, and B reagent RBCs. In addition, the RBCs demonstrated 
reactivity with Glycine soja, but not Arachis hypogaea, Salvia 
horminum, or Salvia sclarea. This constellation of reactivity 
represents an extremely rare form of polyagglutination, not 
formally classified.
The blood bank informed the clinical team that plasma 
components should not be transfused and that units of RBCs 
and PLTs should be washed. Thereafter, the patient received 
multiple units of washed RBCs, although some units could 
not be washed because of staffing issues. The washed units 
of RBCs did not increase the hemoglobin by the expected 
increment. The patient developed anti-M and anti-E; anti-K 
could not be excluded (Fig. 2). All units of RBCs transfused 
during the hospitalization were AHG crossmatch-compatible. 
The severe thrombocytopenia was unresponsive to washed 
PLT transfusions. A course of intravenous dexamethasone 
resulted in concurrent resolution of the thrombocytopenia. 
After a complicated 44-day hospital course, the patient was 
transferred to a long-term care facility in stable condition. 
Since recovering from the infective endocarditis, the patient 
continues to see the neurology service at our hospital for 
treatment of his seizure disorder.
Fig. 3 The peripheral blood film from the day after the 
transfusion of fresh frozen plasma showed large aggregates of 
erythrocytes not seen previously. Subsequent blood films showed 
progressively smaller aggregates and the development of severe 
thrombocytopenia. Blood films consistently showed neutrophils 
with toxic changes and few polychromatophilic macrocytes, but no 
spherocytes, schistocytes, or platelet aggregates were seen.
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Discussion
The purpose of this case study is to report on Glycine 
soja polyagglutination, a rarely described condition that has 
not been associated with infection. Polyagglutination is a rare 
condition that can be caused by cryptantigen exposure on RBCs 
through microbial enzyme activity. Because antibodies against 
cryptantigens are naturally occurring, transfusion of blood 
components, which contain plasma, can cause hematologic 
complications. The identification of polyagglutination involves 
lectin panel testing, which is available at reference laboratories 
but not available at most hospital transfusion services. 
Nevertheless, it is important to diagnose polyagglutination 
because patients with this condition are at risk for 
complications following the transfusion of plasma-containing 
blood components. Therefore, if possible, plasma components 
should be avoided, and units of RBCs and PLTs should be 
washed to avoid the passive transfer of antibodies targeting 
cryptantigens.
This report describes a 60-year-old African-American 
man who was found to have Glycine soja polyagglutination 
after developing a severe MRSA infection. Although the 
patient’s clinical course was complex, the patient’s history 
can best be explained by complications of polyagglutination. 
Prior to transfusion, the patient developed severe anemia of 
unknown etiology, possibly due to endogenous antibodies 
binding to the cryptantigens. The passive transfer of donor 
antibodies, targeting cryptantigens, can explain the onset 
of severe RBC agglutination, the forward ABO typing 
discrepancy, and the transfusion-refractory anemia. The 
reverse ABO typing discrepancy can best be explained by 
anti-M, which was first identified 3 weeks post-admission. 
The severe thrombocytopenia that rapidly developed after the 
FFP transfusion can be explained by cryptantigen exposure 
on the PLTs. Unfortunately, transfused units of washed RBCs 
and PLTs did not provide the increase in cell counts that was 
expected. This finding may be due to in vivo cryptantigen 
exposure on the transfused RBCs and PLTs.
Alternative diagnoses do not fully explain the patient’s 
complex hematologic findings. Post-transfusion purpura (PTP) 
can account for the severe thrombocytopenia (PLT <10,000/
mm3), as this occurred 9 days after the FFP transfusion.16 PTP 
is mediated by antibodies against class II HLA molecules or 
PLT-specific antigens, of which antibodies to human platelet 
antigen (HPA)-1a are most common.16 Alternatively, drug-
induced thrombocytopenia, caused by vancomycin, could 
explain the severe thrombocytopenia.16 Studies to identify 
antibodies to HPA were not conducted, so PTP could not be 
formally excluded. However, neither PTP nor drug-induced 
thrombocytopenia is associated with RBC agglutination, 
anemia, or Glycine soja lectin reactivity. Drug-induced 
immune hemolytic anemia, due to piperacillin, can account 
for the positive DAT and anemia,16 although it cannot explain 
the severe thrombocytopenia or Glycine soja reactivity. A 
combination of drug-induced immune hemolytic anemia with 
PTP or drug-induced thrombocytopenia is unlikely, given 
that the onset of RBC agglutination and the rapid and severe 
decline in PLT count were temporally concurrent with the 
transfusion of FFP.
Glycine soja polyagglutination is distinct from other 
microbial-induced forms such as T activation (the most 
common form) or Th (an incomplete form of T activation), 
Tk, and Tx polyagglutination. Other unique features of 
Glycine soja polyagglutination include its association with 
S. aureus, RBC agglutination refractory to 37°C warming, and 
thrombocytopenia occurring in the absence of DIC. 
Reports of Glycine soja polyagglutination have been 
described. A prospective study screened patients at high risk for 
polyagglutination with the soybean lectin Glycine soja and the 
peanut lectin Arachis hypogaea.17 Two out of 238 patients were 
identified with RBCs that reacted only with Glycine soja. One 
patient was a 71-year-old man with immunoblastic lymphoma. 
The other was a 52-year-old woman with a paravertebral 
mass. The authors included these two patients among a total 
of 18 with reported cryptantigen exposure. The study also 
examined 302 healthy adults in the control group and found 
no lectin reactivity among these patients. Another report of 
Glycine soja polyagglutination described a healthy blood donor 
from Bermuda whose RBCs demonstrated agglutination with 
the majority of recipient sera.18 Interestingly, the agglutination 
was refractory to 37°C warming. Further studies revealed that 
this form of polyagglutination was related to an inherited form 
known as Cad, which represents the strongest expression of 
Sda. The authors named this form CadBer (Ber = Bermuda).
Conclusions
Polyagglutination is a rare, potentially fatal condition 
that may occur in septic patients, causing confounding 
anemia, thrombocytopenia, and DIC. These complications 
may occur in nontransfused patients but are more common 
in patients receiving plasma-containing blood components. 
Polyagglutination can be detected by demonstrating RBC 
agglutination with nearly all compatible adult sera, and lectin 
panel testing can confirm the suspected diagnosis. Transfusion 
protocols such as avoiding plasma components and the use 
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of washed units of PLTs and RBCs are indicated to avoid 
potentially serious complications. Resolution of the underlying 
infection should lead to resolution of polyagglutination.
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